SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

"Solid tumors are often difficult to treat because the immune system within the tumor gets switched off," said Michelle H. Nelson, PhD, Director of Immunobiology at Aptevo. "APVO451 is designed to ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...

This article is based on a poster originally authored by Weiping Sun, Xing Zhang, Zhaolu Yan, Chen Yu, Spencer Chiang, and Tianfu Zhang. Immunotherapy is an advanced and widely used treatment due to ...

GMP ActiveMax ® Human T Cell Activation/Expansion CD3/CD28 Beads are uniform 5.5 μm magnetic beads coated with an optimized mixture of GMP-grade mouse monoclonal antibodies targeting CD3 and CD28, ...

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in ...

Aptevo Therapeutics (APVO) announced the first presentation of preclinical data for its new trispecific antibody, APVO451, at the Society for ...

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells ...

Dr. Simon Plyte, Biomunex's CSO, has been invited to present MAIT engagers preclinical data during an oral communication at 2025 SITC Annual meeting -- With a very attractive safety and efficacy ...